Role of the staphylococcal nuclease and tudor domain containing 1 in oncogenesis (review). 2015

Nidhi Jariwala, and Devaraja Rajasekaran, and Jyoti Srivastava, and Rachel Gredler, and Maaged A Akiel, and Chadia L Robertson, and Luni Emdad, and Paul B Fisher, and Devanand Sarkar
Department of Human and Molecular Genetics, Virginia Commonwealth University, Richmond, VA, USA.

The staphylococcal nuclease and tudor domain containing 1 (SND1) is a multifunctional protein overexpressed in breast, prostate, colorectal and hepatocellular carcinomas and malignant glioma. Molecular studies have revealed the multifaceted activities of SND1 involved in regulating gene expression at transcriptional as well as post-transcriptional levels. Early studies identified SND1 as a transcriptional co-activator. SND1 is also a component of RNA-induced silencing complex (RISC) thus mediating RNAi function, a regulator of mRNA splicing, editing and stability, and plays a role in maintenance of cell viability. Such diverse actions allow the SND1 to modulate a complex array of molecular networks, thereby promoting carcinogenesis. Here, we describe the crucial role of SND1 in cancer development and progression, and highlight SND1 as a potential target for therapeutic intervention.

UI MeSH Term Description Entries
D009369 Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms. Benign Neoplasm,Cancer,Malignant Neoplasm,Tumor,Tumors,Benign Neoplasms,Malignancy,Malignant Neoplasms,Neoplasia,Neoplasm,Neoplasms, Benign,Cancers,Malignancies,Neoplasias,Neoplasm, Benign,Neoplasm, Malignant,Neoplasms, Malignant
D009687 Nuclear Proteins Proteins found in the nucleus of a cell. Do not confuse with NUCLEOPROTEINS which are proteins conjugated with nucleic acids, that are not necessarily present in the nucleus. Nucleolar Protein,Nucleolar Proteins,Nuclear Protein,Protein, Nuclear,Protein, Nucleolar,Proteins, Nuclear,Proteins, Nucleolar
D002268 Carboxypeptidases Enzymes that act at a free C-terminus of a polypeptide to liberate a single amino acid residue. Carboxypeptidase
D002471 Cell Transformation, Neoplastic Cell changes manifested by escape from control mechanisms, increased growth potential, alterations in the cell surface, karyotypic abnormalities, morphological and biochemical deviations from the norm, and other attributes conferring the ability to invade, metastasize, and kill. Neoplastic Transformation, Cell,Neoplastic Cell Transformation,Transformation, Neoplastic Cell,Tumorigenic Transformation,Cell Neoplastic Transformation,Cell Neoplastic Transformations,Cell Transformations, Neoplastic,Neoplastic Cell Transformations,Neoplastic Transformations, Cell,Transformation, Cell Neoplastic,Transformation, Tumorigenic,Transformations, Cell Neoplastic,Transformations, Neoplastic Cell,Transformations, Tumorigenic,Tumorigenic Transformations
D004720 Endonucleases Enzymes that catalyze the hydrolysis of the internal bonds and thereby the formation of polynucleotides or oligonucleotides from ribo- or deoxyribonucleotide chains. EC 3.1.-. Endonuclease
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012326 RNA Splicing The ultimate exclusion of nonsense sequences or intervening sequences (introns) before the final RNA transcript is sent to the cytoplasm. RNA, Messenger, Splicing,Splicing, RNA,RNA Splicings,Splicings, RNA
D015972 Gene Expression Regulation, Neoplastic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in neoplastic tissue. Neoplastic Gene Expression Regulation,Regulation of Gene Expression, Neoplastic,Regulation, Gene Expression, Neoplastic
D058990 Molecular Targeted Therapy Treatments with drugs which interact with or block synthesis of specific cellular components characteristic of the individual's disease in order to stop or interrupt the specific biochemical dysfunction involved in progression of the disease. Targeted Molecular Therapy,Molecular Targeted Therapies,Molecular Therapy, Targeted,Targeted Molecular Therapies,Targeted Therapy, Molecular,Therapy, Molecular Targeted,Therapy, Targeted Molecular
D034622 RNA Interference A gene silencing phenomenon whereby specific dsRNAs (RNA, DOUBLE-STRANDED) trigger the degradation of homologous mRNA (RNA, MESSENGER). The specific dsRNAs are processed into SMALL INTERFERING RNA (siRNA) which serves as a guide for cleavage of the homologous mRNA in the RNA-INDUCED SILENCING COMPLEX. DNA METHYLATION may also be triggered during this process. Gene Silencing, Post-Transcriptional,Post-Transcriptional Gene Silencing,Co-Suppression,Cosuppression,Posttranscriptional Gene Silencing,RNA Silencing,RNAi,Co Suppression,Gene Silencing, Post Transcriptional,Gene Silencing, Posttranscriptional,Gene Silencings, Posttranscriptional,Interference, RNA,Post Transcriptional Gene Silencing,Post-Transcriptional Gene Silencings,Silencing, Post-Transcriptional Gene

Related Publications

Nidhi Jariwala, and Devaraja Rajasekaran, and Jyoti Srivastava, and Rachel Gredler, and Maaged A Akiel, and Chadia L Robertson, and Luni Emdad, and Paul B Fisher, and Devanand Sarkar
January 2024, Neoplasia (New York, N.Y.),
Nidhi Jariwala, and Devaraja Rajasekaran, and Jyoti Srivastava, and Rachel Gredler, and Maaged A Akiel, and Chadia L Robertson, and Luni Emdad, and Paul B Fisher, and Devanand Sarkar
April 2008, International journal for parasitology,
Nidhi Jariwala, and Devaraja Rajasekaran, and Jyoti Srivastava, and Rachel Gredler, and Maaged A Akiel, and Chadia L Robertson, and Luni Emdad, and Paul B Fisher, and Devanand Sarkar
February 2024, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae,
Nidhi Jariwala, and Devaraja Rajasekaran, and Jyoti Srivastava, and Rachel Gredler, and Maaged A Akiel, and Chadia L Robertson, and Luni Emdad, and Paul B Fisher, and Devanand Sarkar
November 2016, Cell death and differentiation,
Nidhi Jariwala, and Devaraja Rajasekaran, and Jyoti Srivastava, and Rachel Gredler, and Maaged A Akiel, and Chadia L Robertson, and Luni Emdad, and Paul B Fisher, and Devanand Sarkar
March 2013, Fish & shellfish immunology,
Nidhi Jariwala, and Devaraja Rajasekaran, and Jyoti Srivastava, and Rachel Gredler, and Maaged A Akiel, and Chadia L Robertson, and Luni Emdad, and Paul B Fisher, and Devanand Sarkar
September 2019, Hepatology communications,
Nidhi Jariwala, and Devaraja Rajasekaran, and Jyoti Srivastava, and Rachel Gredler, and Maaged A Akiel, and Chadia L Robertson, and Luni Emdad, and Paul B Fisher, and Devanand Sarkar
December 2021, Bioengineered,
Nidhi Jariwala, and Devaraja Rajasekaran, and Jyoti Srivastava, and Rachel Gredler, and Maaged A Akiel, and Chadia L Robertson, and Luni Emdad, and Paul B Fisher, and Devanand Sarkar
November 2020, Genomics,
Nidhi Jariwala, and Devaraja Rajasekaran, and Jyoti Srivastava, and Rachel Gredler, and Maaged A Akiel, and Chadia L Robertson, and Luni Emdad, and Paul B Fisher, and Devanand Sarkar
July 2008, Biochemical and biophysical research communications,
Nidhi Jariwala, and Devaraja Rajasekaran, and Jyoti Srivastava, and Rachel Gredler, and Maaged A Akiel, and Chadia L Robertson, and Luni Emdad, and Paul B Fisher, and Devanand Sarkar
June 2014, FEBS letters,
Copied contents to your clipboard!